Stocktoria
Takeda Pharmaceutical Company Limited 4502.T
Takeda Pharmaceutical Company Limited statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value (¥3,539.07); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Takeda Pharmaceutical Company Limited trades at about 47.1× earnings — near its 10-year norm (10-year range 22.3×–64.5×, median 45.6×).
Shaded band = 10-year range (22.3×–64.5×); dot = today's 47.1×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Gross margin | 65.1% | 65.5% | 66.5% | 69.1% |
| Operating margin | 10.3% | 10.2% | 7.3% | 14.6% |
| Net margin | -3.4% | 2.4% | 3.4% | 7.9% |
| FCF margin | 13.9% | 14.8% | 5.5% | 8.5% |
| Return on assets | -1.0% | 0.8% | 1.0% | 2.3% |
| Return on equity | -2.1% | 1.6% | 2.0% | 5.0% |
| Debt / equity | 0.59× | 0.57× | 0.62× | 0.64× |
| Current ratio | 1.09 | 1.01 | 1.11 | 0.97 |
Computed from company filings · JP · as of 2026-03-31. Figures in JPY. Facts plus Stocktoria's own computed scores — not investment advice.